NANJING MINGDE DRUG R & D CO LTD has a total of 11 patent applications. Its first patent ever was published in 2014. It filed its patents most often in China. Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and environmental technology are PHARMABLOCK NANJING R & D CO LTD, QUANTICEL PHARMACEUTICALS INC and GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 11 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Chen Shuhui | 9 |
#2 | Ding Zhaozhong | 5 |
#3 | Liu Xile | 4 |
#4 | Zhang Lu | 3 |
#5 | Wan Haiwen | 3 |
#6 | Zhang Yang | 2 |
#7 | Li Jian | 2 |
#8 | Wu Lingyun | 2 |
#9 | Hu Lihong | 2 |
#10 | Luo Wei | 2 |
Publication | Filing date | Title |
---|---|---|
CN106008503A | Spiro aryl sulfone as protein kinase inhibitor | |
CN106946909A | The nitro imidazole derivatives for the treatment of pulmonery tuberculosis disease | |
CN106800551A | Andrographolide changes structure compound | |
CN105622531A | Axial chiral isomers and preparation method and pharmaceutical application thereof | |
CN105330595A | Pyridine derivative and application thereof to mycobacterium resistance | |
CN105330698A | Spiro aryl phosphorus oxide or sulfide | |
CN105461711A | Pyrido[1,2-a]pyrimidone analogs as PI3K inhibitors | |
CN105461712A | Pyrido[1,2-a]pyrimidone analogs as mTOR/PI3K inhibitors |